4/A: P3 Health Director's RSU Grant & Post-Split Holdings Update

P3 Health Partners Director Gregory N. Kazarian received a grant of 2,000 restricted stock units, with the filing also correcting his beneficial ownership post-reverse stock split.

Summary

• Director Gregory N. Kazarian was granted 2,000 Restricted Stock Units (RSUs) of P3 Health Partners Inc. Class A Common Stock on August 6, 2025.
• The RSUs were issued pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan, with each RSU representing a right to receive one share of Class A common stock.
• The RSUs are scheduled to vest upon the earlier of the Company's 2026 annual stockholder meeting or the one-year anniversary of the grant date (August 6, 2026).
• This filing is an amendment (Form 4/A) to correct an error in the original Form 4, specifically in Column 5 of Table I, which previously reported the number of securities beneficially owned prior to the Company's 1-for-50 reverse stock split.
• The 1-for-50 reverse stock split became effective on April 11, 2025.
• Following this transaction and the correction, Gregory N. Kazarian beneficially owns 6,331 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The RSU grant to the director is a positive event as it aligns management's interests with long-term shareholder value. The amendment itself is a neutral, procedural correction to ensure accurate reporting post-reverse stock split.

Positives

• The grant of 2,000 Restricted Stock Units (RSUs) to Director Gregory N. Kazarian aligns his interests with long-term shareholder value.
• The amendment provides clarity and accuracy regarding the director's beneficial ownership following the company's reverse stock split, enhancing transparency.

Negatives

• The necessity of filing an amendment indicates an initial error in reporting beneficial ownership, which required correction.

Future Outlook

The future outlook includes the vesting of the granted Restricted Stock Units (RSUs) for Director Gregory N. Kazarian, which is scheduled to occur upon the earlier of the Company's 2026 annual stockholder meeting or the one-year anniversary of the grant date (August 6, 2026).

Industry Context

This filing primarily details an insider transaction and a correction to beneficial ownership, which are standard corporate governance and compliance activities. RSU grants are a common form of equity compensation for directors across various industries, designed to align their long-term interests with those of shareholders. The reverse stock split, while not detailed in its rationale here, is a corporate action often undertaken to meet listing requirements or improve share price perception.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased transparency regarding director's holdings; director's interests are further aligned with long-term share price performance due to RSU vesting.
• Management/Directors: Director Gregory N. Kazarian receives equity compensation, incentivizing performance and retention.

Next Steps

• Vesting of the 2,000 RSUs upon the earlier of the Company's 2026 annual stockholder meeting or the one-year anniversary of the grant date (August 6, 2026).

Key Dates

Recommendation

This Form 4/A primarily reports an insider equity grant and a correction to beneficial ownership post-reverse stock split. The RSU grant to a director is a standard compensation practice that aligns management incentives with shareholder interests, which is a minor positive. The amendment itself is a procedural correction, not indicative of new fundamental information. Without broader financial context or strategic updates, this filing does not provide a basis for a significant change in investment recommendation, thus a 'hold' is appropriate.

Keywords

P3 Health Partners, PIII, Gregory N. Kazarian, Form 4/A, SEC filing, RSU, Restricted Stock Units, Director, Stock Split, Beneficial Ownership, Insider Transaction